- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Pharmaceutical
Ariad asks court to restore patent-suit win against Lilly
December 8, 2009
IBJ StaffA federal appeals court will decide whether Eli Lilly and Co. must pay $65.2 million in damages, plus royalties, over a drug-patent
claim.
MoreBuilder looks to cold storage for steady work in a weak economy
December 5, 2009
Brock BenefielCold storage might become a hot business for a building contractor.
MorePart of Mississippi's Zyprexa case against Lilly dismissed
December 2, 2009
IBJ StaffIndianapolis-based Eli Lilly and Co. has won a bid to dismiss part of a negligence lawsuit brought by Mississippi that alleges
improper marketing of antipsychotic drug Zyprexa for unapproved uses.
MoreLilly extends research pact with India firm
December 1, 2009
IBJ StaffJubilant Organosys Ltd. and Indianapolis-based Eli Lilly and Co. extended their collaboration, which began in 2005, by five
years.
MoreLilly's Cymbalta wins new approval for anxiety disorder
November 30, 2009
J.K. WallFDA action should boost sales of the Eli Lilly and Co. drug, which were already on pace to top $3 billion this year.
MoreLilly stock droops after rival claims faster-acting impotence pill
November 18, 2009
IBJ StaffCalifornia-based Vivus claims its drug acts in 30 minutes, compared with about 2 hours for Lilly's Cialis.
MoreAarden Pharmaceuticals chose Indianapolis over San Diego for headquarters
November 14, 2009
IBJ StaffThanks partly to a state grant and support from Indiana’s BioCrossroads life sciences initiative, principals “decided
locating here would give Aarden a better chance of success.
MoreLilly to pay Utah $24 million to settle Zyprexa suit
November 11, 2009
Eli Lilly and Co. has agreed to pay Utah $24 million to settle a lawsuit claiming the company improperly marketed the antipsychotic
drug Zyprexa.
MoreLilly to move 1,000 from Faris campus
October 26, 2009
J.K. WallAs it shrinks its work force, Indianapolis-based pharmaceutical firm Eli Lilly and Co. will move more than 1,000 employees
to its corporate
center
by mid-2010.
MoreLilly needs to sell more Effient before Zyprexa loses patent protection
October 24, 2009
J.K. WallSales of Eli Lilly and Co.’s newest drug were an afterthought during its Oct. 21 report on third-quarter earnings. The
blood thinner Effient totaled up $22.6 million in sales—a mere 0.4 percent of Lilly’s total for
the quarter.
MoreLilly settles Zyprexa case with S. Carolina for $45M
October 23, 2009
IBJ Staff and Associated PressSouth Carolina Attorney General Henry McMaster said Friday that the state has reached a $45 million settlement with drug maker
Eli Lilly and Co. over the company's marketing of an anti-psychotic drug.
MoreEli Lilly CEO banking on new drug pipeline
October 22, 2009
Associated PressCEO John Lechleiter says Lilly's pipeline has helped it rebound from significant patent losses three times during his 30-year
career at the company. He's betting there will be a fourth.
MoreLilly, GE announce cancer diagnostic breakthrough
October 21, 2009
J.K. WallEli Lilly and Co. and General Electric Co. say they've made a breakthrough in cancer research that could help Lilly cut the
size and cost of its clinical trials.
MoreUncertainty over drug pipeline sends Lilly shares down
October 21, 2009
J.K. WallFor the first time publicly, Eli Lilly and Co. officials admitted the obvious: Their pipeline products
aren't likely to offset the revenue the company will lose after its two bestsellers, Zyprexa and Cymbalta, lose patent exclusivity.
MoreLilly reports $942 million profit in third quarter
October 21, 2009
J.K. WallExcluding special items, Eli Lilly and Co.'s earnings per share spike 22 percent on the strength of Alimta, Cymbalta and Humalog
sales. Lilly's revenue rose 7 percent in the quarter over the same period of 2008,
to $5.56 billion.
MoreMedco plans to compare Plavix, Effient in study
October 20, 2009
IBJ Staff and Associated PressMedco Health Solutions Inc. said Tuesday it will compare the blood thinner Plavix, the world's second-best selling drug, with
Effient, a potential blockbuster drug sold by Indianapolis-based Eli Lilly and Co.
MoreEndocyte receives $26M infusion from investors
October 16, 2009
West Lafayette-based Endocyte Inc. announced Friday that it has closed on $26 million in equity financing to help the company
continue developing cancer-fighting drugs.
MoreLilly to pay Idaho $13M in drug settlement
October 14, 2009
IBJ Staff and Associated PressIdaho is getting $13 million as part of a settlement reached with Indianapolis-based Eli Lilly and Co. over its marketing
of
anti-psychotic drug Zyprexa.
MoreLilly to sell Lafayette plant to German firm
October 14, 2009
J.K. WallNearly 700 workers will be offered severance, new jobs
MoreLilly settles Zyprexa suit with S. Carolina
October 7, 2009
IBJ StaffEli Lilly and Co. has agreed to settle the State of South Carolina's lawsuit that claimed Lilly improperly marketed the antipsychotic
drug Zyprexa, according to Bloomberg News.
MoreLilly's win in Evista patent case crucial, analyst says
September 24, 2009
Scott OlsonA decision by a federal judge in Indianapolis to turn back a patent challenge to Eli Lilly and Co.'s Evista marks a major
victory for the company, says an analyst who closely follows the pharmaceutical industry.
MoreJudge upholds Lilly's Evista patent
September 24, 2009
J.K. WallA federal judge in Indianapolis turned back a patent challenge to Eli Lilly and Co.’s drug Evista, the company announced
late yesterday.
MoreLilly agrees to settle more state Zyprexa suits
September 22, 2009
Eli Lilly and Co. has agreed to confidential terms to settle lawsuits brought by seven states alleging the company illegally
marketed bestselling antipsychotic drug Zyprexa, Bloomberg News reported today.
MoreUPDATE: Pipeline challenges force Lilly restructuring moves
September 14, 2009
J.K. WallSince John Lechleiter was named CEO 18 months ago, he's bet that Eli Lilly and Co. could face down its looming patent challenges
by launching innovative new medicines. Today's announcement of 5,500 job cuts by the end of 2011 and a restructuring of the
company's business units ups the ante on that bet, while indicating that it isn't working yet.
MoreLilly reorganization to cut 5,500 positions over 2 years
September 14, 2009
J.K. WallEli Lilly and Co. will cut 5,500 jobs by the end of 2011 as it tries to cut $1 billion in expenses before it loses revenue
from its bestselling drug, Zyprexa. Lilly CEO John Lechleiter said he did not know how many of those cuts would occur in central
Indiana. But with
13,600 employees working in the Indianapolis area, he acknowledged the largest chunk of reductions likely would come here.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
See, I told u Indyman and Dipsicle....this 8 days is overkill. It's barely worth a weekend....great job Tony George! Your dream has been fulfilled....he fans want the I r l back. Thats how good it was.....and that sucked.
I have been in training for a short time now but right off I can see that safety and quality are the number one issues, my experience as of late has been a positive one, the employees along with Jeff the plant manager and the operation supervisor as well as the engineers are a highly motivated group of people, what an asset for the area to have and for company's in need of a quality metal products.
Pimlico
While I understand the severity of their actions as well as everyones eagerness to hold them responsible for thier lost funds, these gentlemen did know how to make money. Dispite thier poor decisions over the ownership of Fair they had made several wise investments which paid them greatly. This proves they do have the potential to rebuild so they can repay. I do not feel they should live the life of luxuary but given an opportunity could they find ways of repaying the debts? They are doing nothing now but being a burden on tax payers. Just a thought!!!!!
You guys have some "interesting" comments to say the least. I hope you will call in and share those opinions starting June 1. I'm looking forward to having you on the air.